Rhumbline Advisers Has $395,000 Stake in MeiraGTx Holdings PLC $MGTX

Rhumbline Advisers boosted its holdings in shares of MeiraGTx Holdings PLC (NASDAQ:MGTX) by 6.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 58,227 shares of the company’s stock after buying an additional 3,336 shares during the quarter. Rhumbline Advisers owned about 0.07% of MeiraGTx worth $395,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Nuveen Asset Management LLC increased its position in MeiraGTx by 43.2% during the fourth quarter. Nuveen Asset Management LLC now owns 191,311 shares of the company’s stock worth $1,165,000 after buying an additional 57,737 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in MeiraGTx by 23.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,275 shares of the company’s stock worth $160,000 after buying an additional 5,010 shares during the last quarter. GAMMA Investing LLC lifted its position in MeiraGTx by 3,606.7% during the 1st quarter. GAMMA Investing LLC now owns 4,448 shares of the company’s stock worth $30,000 after acquiring an additional 4,328 shares during the last quarter. Deutsche Bank AG lifted its position in MeiraGTx by 45.1% during the 4th quarter. Deutsche Bank AG now owns 42,198 shares of the company’s stock worth $257,000 after acquiring an additional 13,111 shares during the last quarter. Finally, ProShare Advisors LLC lifted its position in MeiraGTx by 41.2% during the 4th quarter. ProShare Advisors LLC now owns 16,814 shares of the company’s stock worth $102,000 after acquiring an additional 4,910 shares during the last quarter. 67.48% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Wall Street Zen raised shares of MeiraGTx from a “sell” rating to a “hold” rating in a research report on Saturday, July 5th. Chardan Capital reissued a “buy” rating and set a $35.00 target price on shares of MeiraGTx in a research report on Friday, August 15th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $24.00.

Insider Transactions at MeiraGTx

In other news, CEO Alexandria Forbes sold 47,500 shares of the company’s stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $7.97, for a total transaction of $378,575.00. Following the completion of the transaction, the chief executive officer owned 1,361,483 shares of the company’s stock, valued at approximately $10,851,019.51. This represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Richard Giroux sold 24,000 shares of the company’s stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $8.52, for a total transaction of $204,480.00. Following the transaction, the chief financial officer directly owned 853,494 shares of the company’s stock, valued at $7,271,768.88. This represents a 2.74% decrease in their position. The disclosure for this sale can be found here. 7.50% of the stock is currently owned by corporate insiders.

MeiraGTx Stock Up 1.7%

Shares of MGTX opened at $8.29 on Thursday. The company has a 50-day simple moving average of $7.85 and a 200-day simple moving average of $6.89. The firm has a market capitalization of $666.91 million, a P/E ratio of -4.06 and a beta of 1.29. The company has a debt-to-equity ratio of 26.29, a quick ratio of 0.88 and a current ratio of 0.88. MeiraGTx Holdings PLC has a 52 week low of $3.97 and a 52 week high of $8.98.

MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. The business had revenue of $3.69 million during the quarter, compared to analyst estimates of $8.00 million. MeiraGTx had a negative net margin of 415.39% and a negative return on equity of 314.44%. On average, equities research analysts expect that MeiraGTx Holdings PLC will post -1.48 earnings per share for the current year.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.